Pallas Capital Advisors LLC Makes New $641,000 Investment in Danaher Corporation $DHR

Pallas Capital Advisors LLC purchased a new stake in Danaher Corporation (NYSE:DHRFree Report) during the second quarter, HoldingsChannel.com reports. The fund purchased 3,367 shares of the conglomerate’s stock, valued at approximately $641,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp grew its stake in Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after buying an additional 472,608 shares during the last quarter. Capital International Investors lifted its position in Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after acquiring an additional 1,487,768 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Danaher by 9.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock worth $3,656,595,000 after acquiring an additional 1,334,221 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after acquiring an additional 1,517,904 shares during the period. Finally, Norges Bank acquired a new stake in shares of Danaher in the fourth quarter valued at about $2,177,106,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR opened at $211.92 on Thursday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market cap of $148.98 billion, a P/E ratio of 37.64, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78. The stock’s 50-day moving average price is $194.30 and its two-hundred day moving average price is $192.44.

Danaher (NYSE:DHRGet Free Report) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.77 EPS. On average, equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on DHR. DZ Bank assumed coverage on Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price objective on the stock. Argus lowered their target price on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Piper Sandler began coverage on Danaher in a research report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target on the stock. UBS Group lowered their price objective on shares of Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Stifel Nicolaus reduced their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $228.91.

Check Out Our Latest Research Report on Danaher

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Featured Articles

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.